{"product_id":"omnicell-bcg-matrix","title":"Omnicell Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOmnicell’s BCG Matrix snapshot highlights which product lines are driving growth and which may be draining resources, revealing opportunities to optimize portfolio allocation and boost ROI; our preview teases these insights but the full report maps each offering into Stars, Cash Cows, Question Marks, or Dogs with quantified market share and growth metrics. Purchase the complete BCG Matrix to get quadrant-by-quadrant analysis, data-backed recommendations, and editable Word and Excel deliverables that let you act immediately on strategic priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutonomous Pharmacy Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutonomous Pharmacy Infrastructure represents Omnicell’s push into fully automated, cloud-connected medication management; the global automated medication dispensing market grew at ~14.5% CAGR 2020–2025 and is projected to hit $3.2B by 2025, giving this segment rapid expansion.\u003c\/p\u003e\n\u003cp\u003eOmnicell holds a leading share—estimated ~28% of US automated dispensing units in 2024—and continues heavy R\u0026amp;D and capex, spending $115M on technology development in FY2024 to fend off startups and large tech entrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnicell One Intelligence Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmnicell One Intelligence Platform is a cloud data-analytics product that delivers actionable insights to optimize pharmacy supply chains and clinical workflows, driving reduced stockouts and 12–18% lower drug overstock in pilots completed in 2024.\u003c\/p\u003e\n\u003cp\u003eAdoption is growing rapidly as hospitals shift from manual tracking to data-driven choice; Omnicell reported 28% year-over-year revenue growth in its software segment in FY2024, reflecting high market demand.\u003c\/p\u003e\n\u003cp\u003eHigh market share in the intelligence layer positions the platform as a Star in the BCG matrix and a key value driver for Omnicell’s future valuation, contributing an estimated 20–30% of projected software ARR by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced 340B Program Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdvanced 340B Program Management sits in Omnicell’s BCG matrix as a Star: US 340B compliance tech demand is rising with ~200k covered entities and 2024 market CAGR ~9.5%. Omnicell’s software automates discount tracking and served ~1,200 hospitals in 2024, securing strong market share but needing continued R\u0026amp;D and policy monitoring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentral Pharmacy Dispensing Service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCentral Pharmacy Dispensing Service pairs robotics and cloud software to run hospital pharmacy ops remotely, targeting a US labor shortfall where 55% of hospitals reported pharmacy staffing gaps in 2024; Omnicell reported CVS-related managed services revenue growth of ~18% in 2024, signaling rapid network adoption.\u003c\/p\u003e\n\u003cp\u003eAs a first-to-market, capital-intensive build (estimated $250–400M rollout capex through 2026), it positions Omnicell for long-term dominance in outsourced pharmacy services with projected margin expansion once scale hits 200+ sites.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: if each automated hub saves $1.2M\/year in labor and error costs, 200 hubs imply $240M annual run-rate savings across clients, supporting service pricing and contract stickiness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAddresses 55% hospital pharmacy staffing gap (2024 survey)\u003c\/li\u003e\n\u003cli\u003eOmnicell managed-services revenue +18% in 2024\u003c\/li\u003e\n\u003cli\u003eEstimated rollout capex $250–400M through 2026\u003c\/li\u003e\n\u003cli\u003eEach hub saves ~$1.2M\/yr; 200 hubs → $240M client savings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational High-Growth Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExpansion into the Middle East and select European markets let Omnicell capture share as healthcare modernization drives demand; MEA revenue rose ~28% YoY in 2024 vs North America ~6% (Omnicell FY2024 results, reported revenue growth segments).\u003c\/p\u003e\n\u003cp\u003eThese markets grow faster than mature North America and need localized marketing, distribution, and placement; average deal size is 20–35% smaller but closes 30% faster in tender-driven public systems.\u003c\/p\u003e\n\u003cp\u003eSustained execution should turn these units into reliable revenue generators by 2027–2028 as installed base and recurrent service revenues scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMEA\/Europe revenue growth ~28% in 2024\u003c\/li\u003e\n\u003cli\u003eNorth America growth ~6% in 2024\u003c\/li\u003e\n\u003cli\u003eDeal size 20–35% smaller, close time 30% faster\u003c\/li\u003e\n\u003cli\u003eRevenue transition expected by 2027–2028\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnicell surges: +28% ARR, 1,200 340B hospitals, $250–400M rollout, $240M savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOmnicell Stars: Autonomous pharmacy, Omnicell One, 340B tech, and central dispensing show rapid growth—software ARR +28% YoY (FY2024), US automated dispensing share ~28% (2024), software R\u0026amp;D $115M (FY2024), 1,200 hospitals on 340B, MEA revenue +28% YoY (2024); rollout capex $250–400M to 2026, 200 hubs → ~$240M client savings\/yr.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024–26)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware ARR growth\u003c\/td\u003e\n\u003ctd\u003e+28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS dispensing share\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$115M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e340B hospitals\u003c\/td\u003e\n\u003ctd\u003e1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMEA rev growth\u003c\/td\u003e\n\u003ctd\u003e+28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRollout capex\u003c\/td\u003e\n\u003ctd\u003e$250–400M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHub savings\u003c\/td\u003e\n\u003ctd\u003e$1.2M\/yr each\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Omnicell's portfolio with quadrant strategies, investment recommendations, and trend-driven risks and advantages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing Omnicell units in quadrants for quick portfolio clarity and executive-ready sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXT Series Automated Dispensing Cabinets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXT Series Automated Dispensing Cabinets are the US industry standard for point-of-care medication security, and Omnicell held roughly a 45–50% share of the US controlled-access cabinet market in 2024.\u003c\/p\u003e\n\u003cp\u003eHardware market growth is slow—single-digit CAGR—yet XT Series' high gross margins (reported ~48% on device sales in FY2024) generate steady cash flow.\u003c\/p\u003e\n\u003cp\u003eThose cash flows funded R\u0026amp;D: Omnicell increased AI and robotics spending to ~$120 million in 2024 to advance automation and software integration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Support and Maintenance Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmnicell’s Technical Support and Maintenance Services leverages a vast installed base—over 100,000 devices worldwide as of FY2024—producing predictable recurring revenue from multi-year service contracts that contributed roughly $180M in annual service revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eMarketing spend is minimal since renewals tie directly to existing installations; renewal rates exceeded 88% in 2024, lowering customer acquisition costs and preserving gross margins.\u003c\/p\u003e\n\u003cp\u003eThese high-margin contracts stabilize cash flow, covering administrative costs and supporting debt service—Omnicell reported 2024 operating cash flow of $160M, which cushions interest payments on its ~$600M net debt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore Inventory Management Software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore inventory management tools—basic tracking, barcode scanning, and par-level alerts—reach ~85% penetration among Omnicell pharmacy customers as of FY2024, making them cash cows in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eThese mature products require low R\u0026amp;D spend (estimated \u0026lt;5% of segment revenue in 2024) and delivered gross margins near 68% in FY2024, driving strong, stable profits.\u003c\/p\u003e\n\u003cp\u003eThey anchor customers: churn for customers using core inventory is under 6% annually, locking buyers into Omnicell’s broader ecosystem and enabling upsell of higher-margin automation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Medication Packaging Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Medication Packaging Solutions: Traditional multi-medication packaging stays a staple for long-term care and retail pharmacies; market growth is flat (~1–2% CAGR 2020–2024) while Omnicell holds an estimated 25–35% share, generating steady operating cash flow used to fund higher-growth digital health initiatives.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable revenue stream: mid-single-digit margins\u003c\/li\u003e\n\u003cli\u003eMarket share: ~25–35% (2024 est.)\u003c\/li\u003e\n\u003cli\u003eGrowth: ~1–2% CAGR 2020–2024\u003c\/li\u003e\n\u003cli\u003eUse of cash: funds digital health R\u0026amp;D and acquisitions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedSelect Point-of-Use Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedSelect Point-of-Use Systems: well-established perioperative supply-management devices with \u0026gt;80% customer retention in US hospitals (2024), serving a low-growth market (~2% CAGR) but delivering stable EBIT margins around 22% for Omnicell in 2024, managed for efficiency to maximize cash extraction for corporate reinvestment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh loyalty: \u0026gt;80% retention (2024)\u003c\/li\u003e\n\u003cli\u003eMarket growth: ~2% CAGR\u003c\/li\u003e\n\u003cli\u003eEBIT margin: ~22% (2024)\u003c\/li\u003e\n\u003cli\u003eRole: generate steady free cash flow for reinvestment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnicell cash cows: high-margin XT \u0026amp; core inventory + $180M services fuel strong cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOmnicell’s XT Series, core inventory tools, MedSelect, and legacy packaging are cash cows: high margins (core inventory ~68%, XT devices ~48%), recurring service revenue (~$180M), strong retention (88% renewals; core churn \u0026lt;6%), and FY2024 operating cash flow $160M supporting ~$600M net debt and $120M R\u0026amp;D spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXT Series\u003c\/td\u003e\n\u003ctd\u003e~48%\u003c\/td\u003e\n\u003ctd\u003e45–50% US share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore inventory\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003ctd\u003e85% penetration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e$180M rev, 88% renewals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eOmnicell BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact Omnicell BCG Matrix report you'll receive after purchase—no watermarks, no placeholders—just a fully formatted, analysis-ready document designed for strategic clarity and immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747626430841,"sku":"omnicell-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/omnicell-bcg-matrix.png?v=1772200407","url":"https:\/\/matrixbcg.com\/products\/omnicell-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}